Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Veradermics (MANE) and Absci (ABSI) shares have surged as investors bet on the hair-loss drug market. Veradermics reported positive trial results for an oral minoxidil tablet, while Absci is developing an AI-designed injectable treatment. Both companies face competition and clinical risks, with no new FDA-approved hair-loss drug since the 1990s.
How this was made
The 30-second read
Why it matters
Both companies have seen substantial share price gains, but the news primarily recaps earlier trial data rather than presenting new disclosures.
Market read
The story is a sector‑level update with modest trading relevance; no immediate actionable catalyst.
What to watch
Out‑of‑pocket payment model for hair‑loss drugs could constrain commercial upside.
Background
The article reviews recent clinical milestones for two U.S. listed biotech firms targeting hair‑loss, comparing them to the GLP‑1 market hype.
Ticker impact
Manadermics reported positive oral minoxidil results in men (April) and mid‑stage data for women (July), driving a 500% rally since its IPO.
Potential modest upside if Phase 3 confirms efficacy; downside risk if further trials disappoint.
Clinical milestones are positive but no FDA approval yet; market may have priced in expectations.
Absci disclosed development of an AI‑designed injectable hair‑loss treatment, contributing to a >100% stock gain in 2026.
Limited near‑term move; significant upside only after clear efficacy data.
Without trial results, the news is more hype than concrete catalyst.
Market effects
Highlights growing investor focus on hair‑loss therapeutics, potentially boosting related biotech stocks.
U.S. biotech sector sees increased attention; Swiss competitor Cosmo NV mentioned but not a US‑listed subject.
Limited to niche biotech segment; no broad market impact.
Counterpoint
Valuations may be overstretched given early‑stage pipelines; price corrections likely if trials stall.
Key entities
- CompanyVeradermics, Incorporated
U.S. biotech developing oral minoxidil for hair loss (ticker MANE).
- CompanyAbsci Corporation
U.S. biotech developing AI‑designed injectable hair‑loss treatment (ticker ABSI).
